This afternoon we watched Viatris drop -3.9% to a price of $8.94 per share. The large-cap Medicinal Chemicals company is now trading -39.55% below its average target price of $14.78. Analysts have set target prices ranging from $10.0 to $35.0 per share for Viatris, and have given the stock an average rating of hold.
The stock has an average amount of shares sold short at 3.4%, and a short ratio of 4.02. The company's insiders own 0.32% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 78.2% of Viatris's shares being owned by this investor type.
Institutions Invested in Viatris
|2023-06-30||Vanguard Group Inc||12%||144,495,498||$1,291,067,335|
|2023-06-30||Davis Selected Advisers, LP||5%||62,948,155||$562,441,791|
|2023-06-30||State Street Corporation||5%||61,286,707||$547,596,752|
|2023-06-30||Price (T.Rowe) Associates Inc||4%||48,499,366||$433,341,855|
|2023-06-30||Geode Capital Management, LLC||2%||26,600,284||$237,673,548|
|2023-06-30||Camber Capital Management LP||2%||22,500,000||$201,037,509|
|2023-06-30||Deerfield Management Company, L.P. (Series C)||1%||17,703,484||$158,180,636|
|2023-06-30||Pacer Advisors, Inc.||1%||15,661,796||$139,938,153|
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Viatris.